Reduced platelet survival following chemotherapy with vinblastine, bleomycin and cis-platinum for testicular teratoma.
Patients receiving combination chemotherapy with vinblastine, bleomycin and cis-platinum for testicular teratoma frequently demonstrated early-onset transient thrombocytopenia. We have shown that this effect is due to reduced platelet survival. The relevant literature is reviewed and it is concluded that this phenomenon may be attributable to drug synergism.
D000328:Adult; D001761:Bleomycin / Q000008:administration & dosage / Q000009:adverse effects*; D001792:Blood Platelets / Q000187:drug effects*; D002470:Cell Survival / Q000187:drug effects; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects*; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D010976:Platelet Count; D013724:Teratoma / Q000188:drug therapy*; D013736:Testicular Neoplasms / Q000188:drug therapy*; D013921:Thrombocytopenia / Q000139:chemically induced*; D014747:Vinblastine / Q000008:administration & dosage / Q000009:adverse effects*
D001761:Bleomycin; D014747:Vinblastine; D002945:Cisplatin